表紙
市場調查報告書

阿茲海默症治療藥、診斷藥的全球市場的未來預測

Global Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2020-2028

出版商 Inkwood Research 商品編碼 628603
出版日期 內容資訊 英文 214 Pages
商品交期: 2-3個工作天內
價格
阿茲海默症治療藥、診斷藥的全球市場的未來預測 Global Alzheimer's Disease Therapeutics and Diagnostics Market Forecast 2020-2028
出版日期: 2020年01月21日內容資訊: 英文 214 Pages
簡介

本報告提供全球阿茲海默症 (AD) 用治療藥、診斷藥的市場未來展望相關分析,產品、技術概要和市場基本結構,主要的促進、阻礙因素,市場整體及各產品、各地區的市場趨勢預測 (今後10年份),相關市場與的關聯性,主要企業簡介等調查。

第1章 調查範圍和分析方法

第2章 摘要整理

  • 市場規模與估計
  • 市場概要

第3章 市場動態

  • 母體市場分析:阿茲海默症的治療藥、診斷藥市場
  • 市場定義
  • 主要的促進因素
  • 主要的阻礙因素

第4章 主要指標

  • 波特的五力分析
    • 新加入廠商的威脅
    • 替代產品的威脅
    • 買主談判力
    • 供應商談判力
    • 跟其他競爭公司的競爭
  • 主要的購買標準
    • 價格
    • 功效
    • 安全性
  • 阿茲海默症治療藥、診斷藥市場流行病學的分析
  • 供應鏈分析
    • 企業合併、收購 (M&A)
    • 原料
    • 製造
    • 批發商
    • 終端用戶
  • 阿茲海默症的階段與症狀
  • 市場機會矩陣
  • 業者情勢
  • 主要的投資相關的洞察

第5章 各治療藥、診斷藥的市場

  • 治療藥
    • 治療藥的明細:藥物的各類型 (已上市/開發平台藥物)
    • 治療藥的明細:各病期
    • 治療藥的明細:學名藥/品牌藥
  • 診斷藥
    • 腰椎穿刺實驗
    • PET (正子放出斷層攝影)
    • 腦波計
    • MRI (磁振造影)
    • CT (電腦斷層攝影)
    • 其他診斷

第6章 各地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 比利時
    • 波蘭
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳洲、紐西蘭
    • 韓國
    • 泰國
    • 印尼
    • 越南
    • 其他
  • 其他的國家 (RoW)
    • 中南美
    • 中東、非洲

第7章 企業概要

  • ALLERGAN PLC
  • AMARANTUS BIOSCIENCE HOLDINGS INC.
  • BAXTER INTERNATIONAL INC.
  • BIOGEN INC.
  • COGNOPTIX, INC.
  • Eisai
  • ELI LILLY & COMPANY
  • F. HOFFMANN-LA ROCHE
  • GE HEALTHCARE
  • JOHNSON & JOHNSON
  • LUPIN LIMITED
  • MERCK & CO. INC.
  • NOVARTIS AG
  • PFIZER INC.
  • SUN PHARMACEUTICALS INDUSTRIES LTD.

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: 16811

KEY FINDINGS

The global Alzheimer's therapeutics and diagnostics market is estimated to record a CAGR of 5.21% during the projected period of 2020-2028. The rising geriatric population, an increase in the pervasiveness of Alzheimers disease, research and development of novel diagnostics technologies, and drugs are the factors predicted to influence market growth.

MARKET INSIGHTS

The scope of the therapeutic market involves segments such as drug, disease, stage, generic, and branded. The diagnostics market consists of diagnostics biomarkers used for Alzheimer's disease. The growing investments in biomarkers for the development of drugs and early detection of Alzheimers disease can lead to higher adoption rates of biomarker-based diagnostics and the development of new therapeutics, boosting the market growth. For example, in 2018, Duke University conducted research programs and clinical trials for the development of blood biomarkers of Alzheimers disease. Intensive research is going on in the field of drugs and medicines that are used for the treatment of Alzheimers disease. The adoption rate of Alzheimer's drugs and biomarkers is high due to the increasing prevalence of the disease worldwide. The market faces the challenges of failure in later stages of clinical trials, strict government regulations for developing and commercializing drugs, and expensive therapies used for Alzheimer's treatment.

REGIONAL INSIGHTS

The global market of Alzheimer's disease therapeutics and diagnostics is analyzed by analyzing the regions of North America, Europe, Asia Pacific, and the Rest of the World. The region is also estimated to garner the largest market share during the forecast period. This is attributed to the growing geriatric population, high spending on healthcare, and the pervasiveness of Alzheimer's disease across the US. The Asia Pacific market region is projected to record the fastest growth rate during the forecasted period.

COMPETITIVE INSIGHTS

The global Alzheimer's disease therapeutics and diagnostics market's competitive nature is fueled by the large presence of major industry players. Some of the well-known companies in the market include, GE Healthcare, Johnson & Johnson, Novartis AG, Sun Pharmaceuticals Industries Ltd., Pfizer Inc., etc.

Our report offerings include:

Explore key findings of the overall market

Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)

Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions

Market Segmentation cater to a thorough assessment of key segments with their market estimations

Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share

Key analytics: Porter's Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.

Competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.

Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

TABLE OF CONTENTS

1. RESEARCH SCOPE & METHODOLOGY

  • 1.1. STUDY OBJECTIVES
  • 1.2. SCOPE OF STUDY
  • 1.3. METHODOLOGY
  • 1.4. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARIES

  • 2.1. MARKET SIZE & ESTIMATES
  • 2.2. MARKET OVERVIEW

3. MARKET DYNAMICS

  • 3.1. PARENT MARKET ANALYSIS: ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
  • 3.2. MARKET DEFINITION
  • 3.3. KEY DRIVERS
    • 3.3.1. GROWING GERIATRIC POPULATION
    • 3.3.2. RISE IN THE PERVASIVENESS OF ALZHEIMER'S DISEASE
    • 3.3.3. EMERGING NOVEL DIAGNOSTIC TECHNOLOGIES
    • 3.3.4. INCREASING PIPELINE DRUGS
  • 3.4. KEY RESTRAINTS
    • 3.4.1. FAILURE OF THE LATE-STAGE DRUGS
    • 3.4.2. STRINGENT GOVERNMENT REGULATIONS
    • 3.4.3. HIGH COST OF THERAPIES USED FOR THE TREATMENT OF ALZHEIMER'S DISEASE

4. KEY ANALYTICS

  • 4.1. PORTER'S FIVE FORCE ANALYSIS
    • 4.1.1. THREAT OF NEW ENTRY
    • 4.1.2. THREAT OF SUBSTITUTION
    • 4.1.3. BUYER'S POWER
    • 4.1.4. SUPPLIER'S POWER
    • 4.1.5. COMPETITIVE RIVALRY
  • 4.2. KEY BUYING CRITERIA
    • 4.2.1. PRICE
    • 4.2.2. EFFICIENCY
    • 4.2.3. SAFETY
  • 4.3. ETYMOLOGY OF ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET
  • 4.4. SUPPLY CHAIN ANALYSIS
    • 4.4.1. RESEARCH AND DEVELOPMENT
    • 4.4.2. RAW MATERIALS
    • 4.4.3. MANUFACTURING
    • 4.4.4. WHOLESALERS
    • 4.4.5. END USER
  • 4.5. PHASES AND STERNNESS OF ALZHEIMER'S DISEASE
  • 4.6. OPPORTUNITY MATRIX
  • 4.7. VENDOR LANDSCAPE
  • 4.8. KEY INVESTMENT INSIGHTS

5. MARKET BY THERAPEUTICS AND DIAGNOSTICS

  • 5.1. THERAPEUTICS
    • 5.1.1. THERAPEUTICS BY DRUGS
      • 5.1.1.1. MARKETED DRUGS
      • 5.1.1.2. PIPELINE DRUGS
    • 5.1.2. THERAPEUTICS BY DISEASE STAGE
      • 5.1.2.1. LATE STAGE: SEVERE AD
      • 5.1.2.2. EARLY/MIDDLE STAGE: MILD TO MODERATE AD
      • 5.1.2.3. PRODROMAL STAGE
    • 5.1.3. THERAPEUTICS BY GENERIC AND BRANDED
      • 5.1.3.1. BRANDED
      • 5.1.3.2. GENERIC
  • 5.2. DIAGNOSTICS
    • 5.2.1. LUMBAR PUNCTURE TEST
    • 5.2.2. POSITRON EMISSION TOMOGRAPHY
    • 5.2.3. ELECTROENCEPHALOGRAPHY
    • 5.2.4. MAGNETIC RESONANCE IMAGING
    • 5.2.5. COMPUTED TOMOGRAPHY
    • 5.2.6. OTHER DIAGNOSTICS

6. GEOGRAPHICAL ANALYSIS

  • 6.1. NORTH AMERICA
    • 6.1.1. THE UNITED STATES
    • 6.1.2. CANADA
  • 6.2. EUROPE
    • 6.2.1. THE UNITED KINGDOM
    • 6.2.2. FRANCE
    • 6.2.3. GERMANY
    • 6.2.4. ITALY
    • 6.2.5. RUSSIA
    • 6.2.6. BELGIUM
    • 6.2.7. POLAND
    • 6.2.8. REST OF EUROPE
  • 6.3. ASIA PACIFIC
    • 6.3.1. CHINA
    • 6.3.2. INDIA
    • 6.3.3. JAPAN
    • 6.3.4. AUSTRALIA & NEW ZEALAND
    • 6.3.5. SOUTH KOREA
    • 6.3.6. THAILAND
    • 6.3.7. INDONESIA
    • 6.3.8. VIETNAM
    • 6.3.9. REST OF ASIA PACIFIC
  • 6.4. REST OF WORLD
    • 6.4.1. LATIN AMERICA
    • 6.4.2. MIDDLE EAST & AFRICA

7. COMPANY PROFILES

  • 7.1. ALLERGAN PLC
  • 7.2. AMARANTUS BIOSCIENCE HOLDINGS INC.
  • 7.3. BAXTER INTERNATIONAL INC.
  • 7.4. BIOGEN INC.
  • 7.5. COGNOPTIX, INC.
  • 7.6. EISAI CO. LTD
  • 7.7. ELI LILLY & COMPANY
  • 7.8. F. HOFFMANN-LA ROCHE
  • 7.9. GE HEALTHCARE
  • 7.10. JOHNSON & JOHNSON
  • 7.11. LUPIN LIMITED
  • 7.12. MERCK & CO. INC.
  • 7.13. NOVARTIS AG
  • 7.14. PFIZER INC.
  • 7.15. SUN PHARMACEUTICALS INDUSTRIES LTD.

LIST OF TABLES

  • TABLE 1: MARKET SNAPSHOT - ALZHEIMER'S DISEASE AND THERAPEUTICS
  • TABLE 2: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 3: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS AND DIAGNOSTICS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 4: GLOBAL THERAPEUTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 5: GLOBAL THERAPEUTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 6: GLOBAL THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 7: GLOBAL THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 8: GLOBAL MARKETED DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 9: GLOBAL MARKETED DRUGS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 10: GLOBAL PIPELINE DRUGS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 11: GLOBAL PIPELINE DRUGS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 12: GLOBAL THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 13: GLOBAL THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 14: GLOBAL LATE STAGE: SEVERE AD MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 15: GLOBAL LATE STAGE: SEVERE AD MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 16: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 17: GLOBAL EARLY/MIDDLE STAGE: MILD TO MODERATE AD MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 18: GLOBAL PRODROMAL STAGE MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 19: GLOBAL PRODROMAL STAGE MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 20: GLOBAL THERAPEUTICS MARKET, BY DRUGS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 21: GLOBAL THERAPEUTICS MARKET, BY DRUGS, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 22: GLOBAL BRANDED MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 23: GLOBAL BRANDED MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 24: GLOBAL GENERIC MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 25: GLOBAL GENERIC MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 26: GLOBAL DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 27: GLOBAL DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 28: GLOBAL DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 29: GLOBAL DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 30: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 31: GLOBAL LUMBAR PUNCTURE TEST MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 32: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 33: GLOBAL POSITRON EMISSION TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 34: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 35: GLOBAL ELECTROENCEPHALOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 36: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 37: GLOBAL MAGNETIC RESONANCE IMAGING MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 38: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 39: GLOBAL COMPUTED TOMOGRAPHY MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 40: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 41: GLOBAL OTHER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 42: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 43: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 44: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 45: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 46: EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 47: EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 48: ASIA PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 49: ASIA PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2020-2028 (IN $ MILLION)
  • TABLE 50: REST OF WORLD ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
  • TABLE 51: REST OF WORLD ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2020-2028 (IN $ MILLION)

LIST OF FIGURES

  • FIGURE 1: PIPELINE DRUGS RELATED TO ALZHEIMER'S DISEASE
  • FIGURE 2: COSTS OF CARE FOR PEOPLE WITH ALZHEIMER'S AND OTHER DEMENTIAS, 2017 ($ BILLION)
  • FIGURE 3: PORTER'S FIVE FORCE ANALYSIS
  • FIGURE 4: SUPPLY CHAIN ANALYSIS
  • FIGURE 5: OPPORTUNITY MATRIX
  • FIGURE 6: VENDOR LANDSCAPE
  • FIGURE 7: KEY INVESTMENT INSIGHTS
  • FIGURE 8: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY THERAPEUTICS, 2020-2028 ($ MILLION)
  • FIGURE 9: GLOBAL THERAPEUTICS MARKET, BY MARKETED DRUGS, 2020-2028 ($ MILLION)
  • FIGURE 10: GLOBAL THERAPEUTICS MARKET, BY PIPELINE DRUGS, 2020-2028 ($ MILLION)
  • FIGURE 11: GLOBAL THERAPEUTICS MARKET, BY LATE STAGE: SEVERE AD, 2020-2028 ($ MILLION)
  • FIGURE 12: GLOBAL THERAPEUTICS MARKET, BY EARLY/MIDDLE STAGE: MILD TO MODERATE AD, 2020-2028 ($ MILLION)
  • FIGURE 13: GLOBAL THERAPEUTICS MARKET, BY PRODROMAL STAGE, 2020-2028 ($ MILLION)
  • FIGURE 14: GLOBAL THERAPEUTICS MARKET, BY BRANDED, 2020-2028 ($ MILLION)
  • FIGURE 15: GLOBAL THERAPEUTICS MARKET, BY GENERIC, 2020-2028 ($ MILLION)
  • FIGURE 16: GLOBAL ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, BY DIAGNOSTICS, 2020-2028 ($ MILLION)
  • FIGURE 17: GLOBAL DIAGNOSTICS MARKET, BY LUMBAR PUNCTURE TEST, 2020-2028 ($ MILLION)
  • FIGURE 18: GLOBAL DIAGNOSTICS MARKET, BY POSITRON EMISSION TOMOGRAPHY, 2020-2028 ($ MILLION)
  • FIGURE 19: GLOBAL DIAGNOSTICS MARKET, BY ELECTROENCEPHALOGRAPHY, 2020-2028 ($ MILLION)
  • FIGURE 20: GLOBAL DIAGNOSTICS MARKET, BY MAGNETIC RESONANCE IMAGING, 2020-2028 ($ MILLION)
  • FIGURE 21: GLOBAL DIAGNOSTICS MARKET, BY COMPUTED TOMOGRAPHY, 2020-2028 ($ MILLION)
  • FIGURE 22: GLOBAL DIAGNOSTICS MARKET, BY OTHER DIAGNOSTICS, 2020-2028 ($ MILLION)
  • FIGURE 23: NORTH AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 24: THE UNITED STATES ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 25: CANADA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 26: EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 27: THE UNITED KINGDOM ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 28: FRANCE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 29: GERMANY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 30: ITALY ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 31: RUSSIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 32: BELGIUM ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 33: POLAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 34: REST OF EUROPE ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 35: ASIA PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 36: CHINA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 37: INDIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 38: JAPAN ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 39: AUSTRALIA & NEW ZEALAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 40: SOUTH KOREA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 41: THAILAND ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 42: INDONESIA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 43: VIETNAM ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 44: REST OF ASIA PACIFIC ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 45: REST OF WORLD ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2019 & 2028 (IN %)
  • FIGURE 46: LATIN AMERICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)
  • FIGURE 47: MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE THERAPEUTICS AND DIAGNOSTICS MARKET, 2020-2028 (IN $ MILLION)